contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


combigene-initiates-restructuring-as-part-of-strategic-review-to-maximize-shareholder-value

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

CombiGene's vision is to give patients affected by severe diseases the opportunity for a better life through gene therapy and other forms of advanced treatments. The company's operations have three focus areas: in-licensing of new assets, development of these assets to proof-of-concept, and out-licensing of the assets to a strategic partner for continued development and commercialization. CombiGene is based in Stockholm.

CombiGene

The Board of CombiGene AB (publ) (“CombiGene”, the “Company”) today announces that a first step has been taken in the strategic review that began in December 2024. The purpose of this review...

<div class="mfn-body">The Board of CombiGene AB (publ) (“CombiGene”, the “Company”) today announces that a first step has been taken in the strategic review that began in December 2024. The purpose of this review is to ensure shareholder value. As part of this process, the Board has decided to implement a number of strategic and operational measures to streamline the business and enable a more focused work going forward.Staff reduction and cost-efficiency In order to adapt the business to the current market conditions, the Board has decided to terminate all employment, including the CEO. This is a strategic and necessary step to reduce the Company's fixed costs and enable future strategic choices.The Board would like to emphasize that this decision in no way reflects the employees' performance or competence. On the contrary, their commitment and contribution have been invaluable to both CombiGene and the Swedish research sector within gene therapy.Future of research projects A prioritized part of the strategic review is to ensure that the Company's ongoing research projects are taken forward. The Board will actively evaluate potential partners and external stakeholders who can continue the development of the projects to maximize potential and create value for shareholders.Exploration of new strategic opportunities As part of the restructuring, CombiGene will explore other strategic opportunities in 2025. Primarily, investment opportunities in companies with neutral or positive cash flows will be evaluated. The board sees great value in an offer that includes significant capital, a broad ownership base, and a stock exchange listing.</div><div class="mfn-footer mfn-contacts mfn-954154356e40">Contacts<hr>CombiGene AB (publ) Luca Di Stefano, Chairman of the Board Phone: +46 (0)70 855 67 23 luca.distefano@combigene.com<a rel="noopener" href="https://combigene.com/">www.combigene.com</a> CombiGene AB (publ),&nbsp;Skeppsbron 38, SE-111&nbsp;30&nbsp;Stockholm, Sweden +46-8-357355 <a rel="noopener" href="mailto:info@combigene.com">info@combigene.com</a></div><div class="mfn-footer mfn-about mfn-2840449e81ce">About CombiGene<hr>The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is Västra Hamnen Corporate Finance AB.</div><div class="mfn-footer mfn-regulatory mfn-regulatory-mar">This information is information that CombiGene is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-01-09 08:45 CET.</div><div class="mfn-footer mfn-attachment mfn-attachment-general">Attachments<hr><a rel="noopener" href="https://storage.mfn.se/53bea398-b065-47d1-98f4-61a0a1d33406/combigene-initiates-restructuring-as-part-of-strategic-review-to-maximize-shareholder-value.pdf" class="mfn-generated mfn-primary">CombiGene initiates restructuring as part of strategic review to maximize shareholder value</a></div>

CombiGene initiates restructuring as part of strategic review to maximize shareholder value